Table 1.
Patient characteristics
| Patient | sex | age | Myeloma type | Disease duration (m) | Pre-Treatment with PI/IMiD/Ab |
Sites of extramedullary disease | Previous auto SCT |
Conditioning Regimen (after ERT) |
Best serological response | Best metabolic response |
|---|---|---|---|---|---|---|---|---|---|---|
| 1/1 | m | 62 | Ig G κ | 18 | +/+/+ | Soft tissue, testis | 1x | Melphalan | PR | PR |
| 1/2 | 20 | 2x | HD-BEAM | PR | PR | |||||
| 1/3 | 21 | 3x | Bortezomib, fludarabine, treosulfan | SD | PD | |||||
| 2 | m | 51 | LC λ | 59 | +/+/- | LN, pleura, soft tissue, testis, PCL | 3x | HD-BEAM | VGPR | CR |
| 3 | f | 66 | LC κ | 53 | +/+/- | LN, leptomeningeal | 4x | Melphalan, Carmustine | n/a | n/a |
| 4 | f | 53 | LC κ | 123 | +/+/- | None | 3x | Treosulfan | PR | PR |
| 5 | m | 65 | Ig A κ | 101 | +/+/- | None | 2x | Treosulfan | PR | n/a |
| 6 | m | 62 | Ig G λ | 65 | +/+/- | Soft tissue | 2x | Treosulfan | SD | n/a |
| 7 | m | 68 | LC λ | 148 | +/+/- | LN, liver | 2x | Treosulfan | SD | PR |
| 8 | f | 58 | LC κ | 16 | +/+/- | LN, pleura, soft tissue | 1x | n/a | n/a | n/a |
Response assessment was performed according to IMWG criteria and/or PET/CT imaging results.
Ab = antibody, auto SCT = autologous stem cell transplantation, CR = complete remission, ERT = endoradiotherapy, f = female, HD-BEAM = high-dose chemotherapy consisting of carmustine, etoposide, cytarabine and melphalan, LC = light chain, IMiD = immunomodulatory drugs, LN = lymph node, m = male, PCL = plasma cell leukemia, PD = progressive disease, PI = proteasome inhibitors, PR = partial response, SD = stable disease, VGPR = very good partial response